ACE Inhibitors Market Research Report - Forecast till 2027

ACE Inhibitors Market: Information by Drug (Lisinopril, Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril and  others), Application (Heart Failure, Hypertension, Diabetes, Heart Attack, Chronic Kidney Disease and others), Dosage Form (Oral Tablets and Oral Solution), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites and Online Drug Stores) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/HC/7159-HCR | February 2021 | Region: Global | 118 pages

ACE Inhibitors Market Overview 


Globally it is marked that there is large competition and diversification in the ACE Inhibitors Market. There are some popular drugs available in the market due to dosage inconvenience and higher efficiency which has long-term effects. The chronic hypertension segment was marked as the moving segment in ACE inhibitors throughout the ACE Inhibitors Market forecast period. ACE is the type of drug that inhibits the conversion of Angiotensin I to Angiotensin II which does not allow microvascular compilation of diabetes mellitus. As per WHO it is marked that 17 million people die a year which is nearly one-third of the total. Worldwide it is noted that the complication for ACE accounts for 9.4 million deaths.


If a free drug is eliminated from the kidney by glomerular filtration, forming an active bond to tissue sites thus it is marked that the plasma concentration-time profile gives large longevity eliminating phase. From marketing insights, it is observed that the popular ACE inhibitor, captopril, is fully absorbed and is eliminated gradually. Enalapril is an active proactive drug where the addition of water during or absorption takes place which generates the active form of enalapril. The market scenario provides proper primary and secondary research which enhances the business intelligence solutions.


ACE Inhibitors Market is expected to reach around USD 7682.8 Million by 2025 and is expected to register a CAGR of 3.10% between 2019 and 2025.


COVID 19 ANALYSIS 


COVID had a great impact on the health sector. Many countries are still trying to overcome this virus. Wealth issues arose in the industry. Financial downfall in developing and underdeveloped countries was marked. The downfall of the ACE Inhibitors Market was marked but besides it was also helpful for the patients having heart disease. Holistic mandates in the healthcare regulations put forward by the administrations were noticed.


To tackle the situation, the government of the country took the initiative to impose a lockdown. He took a different approach to control this breakdown which maintained a balance between social and economic aspects. The government has invested funds to carry out that research which gives actionable guidance. 


MARKET DYNAMICS



  • Drivers- launching new innovative products for treating hypertension-are a major factor driving the ACE Inhibitors Market size. Use of new therapies containing Coversyl (having perindopril arginine), Coversyl plus(having perindopril arginine, and indapamide hemihydrate), which are those chemicals that help in treatment. An increase in prevailing hypertension disorder helps in ACE Inhibitors Market growth. This is because India is a country where the majority of people suffer from hypertension disorder.

  • Opportunity- having an obese figure and supportive reimbursement policies provide lucrative opportunities for enhancement in the market. The use of the best products makes them reliable which too aims at building customer experience and engagement.

  • Challenges- the presence of proper healthcare infrastructure and being highly aware of the diagnosis, treatment, and management of the day-to-day disease are the major challenges that promote the growth n the major key players of the ACE Inhibitors Market. Points that increase their revenue potential, increase the demand, and the consumption patterns globally.

  • Cumulative growth- rise in drug approval activities by FDA helps in steering the ACE Inhibitors Market size. More research and developing activities enhance the improvement of cardiovascular function at times of pregnancy boosts up ACE market growth. SWOT analysis will increase the overall market growth.

  • Restraints- if the treatment causes any negative effects on the patient then a decline in market growth will surely take place. If potential cost is not to a limited amount then growth surely hampers. Using societal perspective for a short period minimization of cost should be kept in the notice. Accessing the ACE inhibitor if not restricted then the expenses will not be reduced. If the intake of the drug is stopped then the effect of the ACE inhibitor on the body of the patient may have a negative effect.


VALUE CHAIN ANALYSIS 


Keeping an eye on the ACE inhibitors the supply chain gives a significant surge and which increases the commercial opportunities. The manufacturers carry out various quantitative strategies by which growth will increase.


SEGMENT OVERVIEW



  • By type- ACE drug segment consists of benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril along with the combination of ACE inhibitors. From ACE inhibitors market trends it is marked that these inhibitors bond with tissue and plasma proteins.

  • By technology- new technology provides qualitative and quantitative research thus forms new products which are very friendly. Technology led to the advancement of treatment. The technology provides market projection methodologies and certain customer tools for proper treatment. The advancement of technology protects the customers from disruptive ACE inhibitors market trends.


RECENT DEVELOPMENTS 



  • Silvergate Pharmaceuticals in the year of January 2017, discovered an oral solution of Epaned containing Enalapril for curing hypertension and heart failure, asymptomatic left ventricle dysfunctioning. This has been taken the approval of the FDA and is directed to be used for adults and children.it administered the use of Lisinopril.

  • Novartis Pharmaceuticals in November 2016, discovered Ramipril, Valsartan which helped in the treatment of acute myocardial infarction.

  • The research fellows of Manchester University made a study regarding the evaluation of drug safety on patients. This study was also made regarding the clinical phase II Enalapril Maleate for pre-eclampsia condition. This is a condition where pregnancy complications arise which includes high blood pressure. This condition also includes various signs and symptoms which are characterized by proteinuria, upper abdominal pain, and shortness of breath.


REGIONAL ANALYSIS 


The regional division of the ACE Inhibitors Market constitutes North America, Middle East, the Asia Pacific region, and Africa. Geographically the market is further segmented which provides the marketing expenses for some countries. North America is expected to dominate the largest ACE Inhibitors Market share during the ACE Inhibitors Market forecast period. This is because the region involves several researchers and developmental activities. It is marked that the Asia Pacific region showed high ACE Inhibitors Market growth, providing awareness about hypertension and the ways that will help to prevent it. Europe also covers a significant region during the ACE Inhibitors Market forecast period as it owes to the launching of new products in the European region.


COMPETITIVE LANDSCAPE 


ACE Inhibitors Market consists of dominating competitors who believe in building partnerships or particular relationships with other competitors. They merge or build acquisitions and do worldwide market research. These competitors serve as the growth-promoting associations which assist and bring enhancement that fulfills their objectives. These competitors execute their work properly and evaluate the current growth prospects. The key players that covered the major portion of the ACE Inhibitors Market share are Pfizer Inc., AstraZeneca Pharmaceutical Company, Novartis AG, Johnson, and Johnson Services, United Therapeutics Corporation, Merck KGaA, Teva Pharmaceutical Industry, Sandoz AG, Novartis AG, Bayer AG, Sanofi, etc. these competitors help the industry to plan their strategic ailments which build the complete scenario at uncertain times.


REPORT OVERVIEW 


From the report analysis, it was noted that the Indian Council of Medical Research called a campaign on hypertension and heart failure which made a partnership with the Public Health Foundation in India. It gives proper market insights about the research teams present in the ACE market and also about the firms that play a great role in developmental activities. It gives a good evaluation of the market dynamics, consulting, and competitive services. It also signifies the use of technology in ACE Inhibitors Market trends and also about its growth potential. It follows a research methodology that focuses on providing accurate market analysis and proper estimation. As per the ACE Inhibitors Market analysis, the market report also includes primary and desk research and proprietor data analysis, model. The company dealing with it provides a good analysis from the company perspective which provides good analysis about the ACE Inhibitors Market ecosystem. The report explains the scenario about the segmentation along with the opportunities provided by the industry.



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 7682.8 Million
  CAGR   (3.10%) :2019-2025
  Base Year   2019
  Forecast Period   2025
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors and Trends
  Segments Covered   Drug, Application, Dosage Form, Distribution Channel and Region
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Bristol-Myers Squibb Company, Par Pharmaceutical Companies, Inc., UCB, Pfizer, AbbVie Inc., AstraZeneca Bausch Health Companies, Novartis AG, Merck & Co., Teva Pharmaceutical Industries Ltd., Silvergate Pharmaceuticals
  Key Market Opportunities

  • Innovative products
  • Changing lifestyle
  •   Key Market Drivers

  • Adoption of ACE Inhibitors in the management of chronic disorders
  • Increasing prevalence of hypertension and other cardiovascular disorders
  • Rising demand for less expensive drugs


  • Frequently Asked Questions (FAQ) :


    ACE Inhibitors Market is projected to grow at approximately 3.10% CAGR during the assessment period (2019-2025).

    ACE Inhibitors Market is estimated to reach a valuation of approx. USD 7682.8 MN by the end of 2025

    Rising adoption of ACE inhibitors for the treatment of cardiovascular complications and diabetic neuropathy, are major tailwinds pushing the growth of the global ACE inhibitors market.

    North America holds the largest share in the Global ACE Inhibitors Market, followed by Europe and the Asia Pacific, respectively.

    Par Pharmaceutical Companies, Inc. (US), Merck & Co., Inc.(US), Bristol-Myers Squibb Company (US), Teva Pharmaceutical Industries Ltd.(Israel), UCB, Inc. (Belgium), AstraZeneca (UK), AbbVie Inc.(US), Novartis AG (Switzerland), Pfizer, Inc.(US), Bausch Health Companies Inc.(Canada), and Silvergate Pharmaceuticals, Inc. (US), are some of the top players operating in the Global ACE Inhibitors Market.



    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.